A

Amerisourcebergen Corp
LSE:0HF3

Watchlist Manager
Amerisourcebergen Corp
LSE:0HF3
Watchlist
Price: 250.71 USD 0.33% Market Closed
Market Cap: 52B USD
Have any thoughts about
Amerisourcebergen Corp?
Write Note

Amerisourcebergen Corp
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Amerisourcebergen Corp
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
A
Amerisourcebergen Corp
LSE:0HF3
Operating Income
$3B
CAGR 3-Years
4%
CAGR 5-Years
10%
CAGR 10-Years
15%
Cardinal Health Inc
NYSE:CAH
Operating Income
$2.2B
CAGR 3-Years
7%
CAGR 5-Years
3%
CAGR 10-Years
0%
Henry Schein Inc
NASDAQ:HSIC
Operating Income
$608m
CAGR 3-Years
-10%
CAGR 5-Years
-4%
CAGR 10-Years
-1%
Patterson Companies Inc
NASDAQ:PDCO
Operating Income
$244.1m
CAGR 3-Years
4%
CAGR 5-Years
10%
CAGR 10-Years
-1%
Mckesson Corp
NYSE:MCK
Operating Income
$3.8B
CAGR 3-Years
-3%
CAGR 5-Years
4%
CAGR 10-Years
4%
Cencora Inc
NYSE:COR
Operating Income
$3B
CAGR 3-Years
4%
CAGR 5-Years
10%
CAGR 10-Years
15%
No Stocks Found

Amerisourcebergen Corp
Glance View

Market Cap
48.9B USD
Industry
Health Care
Economic Moat
None

AmerisourceBergen Corp. is a leading healthcare services company that plays an essential role in the pharmaceutical supply chain, connecting manufacturers, healthcare providers, and patients. Founded in 2001 and headquartered in Chesterbrook, Pennsylvania, the company has grown through strategic acquisitions and an unwavering commitment to improving patient access to critical medications. AmerisourceBergen stands out by providing a wide range of services, including drug distribution, specialty pharmacy solutions, and healthcare consulting, making it a vital partner for thousands of healthcare organizations across the United States and beyond. By prioritizing innovation and efficiency, they not only streamline pharmaceutical delivery but also enhance patient care in an increasingly complex healthcare landscape. As investors consider AmerisourceBergen, they can take comfort in the company’s impressive financial performance and resilience against market fluctuations. With a robust revenue stream primarily generated from the distribution of pharmaceuticals, AmerisourceBergen benefits from the growing demand for healthcare products and services. Additionally, the company's strategic partnerships and investment in technology position it well for future growth, particularly in the specialty drug sector, which is expanding rapidly due to the rise of biologics and personalized medicine. AmerisourceBergen's focus on operational excellence and customer satisfaction not only fosters loyalty among its clients but also supports a stable and attractive investment outlook, making it a compelling option for those looking to capitalize on the evolving healthcare market.

0HF3 Intrinsic Value
454.73 USD
Undervaluation 45%
Intrinsic Value
Price
A

See Also

What is Amerisourcebergen Corp's Operating Income?
Operating Income
3B USD

Based on the financial report for Sep 30, 2024, Amerisourcebergen Corp's Operating Income amounts to 3B USD.

What is Amerisourcebergen Corp's Operating Income growth rate?
Operating Income CAGR 10Y
15%

Over the last year, the Operating Income growth was 20%. The average annual Operating Income growth rates for Amerisourcebergen Corp have been 4% over the past three years , 10% over the past five years , and 15% over the past ten years .

Back to Top